As the IP community waits for movement on the Biden Administration’s proposal to expand the scope of the march-in rights provision under the Bayh-Dole Act, the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) has been actively countering the administration’s argument that such a mechanism would effectively lower drug prices. The comment period for the National Institute of Standards & Technology (NIST) and the Department of Commerce’s Request for Information (RFI) on the proposal closed in early February. Since then, it has been rumored several times that the framework would be finalized and published, but those rumors never materialized.
Recent Posts
- Other Barks and Bites for Friday, January 17: Teva Files IRA Challenge Amid Second Round of Medicare Negotiations; Ninth Circuit Says Kinetic Sculptures Can Be Sufficiently ‘Fixed’ for Copyright; USPTO Publishes Inventorship FAQs for AI-Assisted Inventions
- USPTO Fee Report: Discounts Don’t Cut It for Incentivizing New Patent Participants
- Federal Circuit Splits on Whether Toddler Tub May Infringe
- CAFC Rules Patent Applications are Considered Pre-AIA Prior Art By Filing Date, Not Publication Date
- The Biden Administration Rolls the Dice on NIH Patent Licensing